About Us | Contact

Dr. L. Eugene Arnold Investigator

Child & Adolescent Psychiatry NPI1902829492
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$7,338.20
from 17 payments in the last 6 years

Total Cash or Cash Equivalent

$4,299.75
from 4 payments in the last 6 years

Total In-kind Items & Services

$3,038.45
from 13 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
11/12/2019 Research Cash or cash equivalent Drug $47.00 Details
Payment from Otsuka Pharmaceutical Development & Commercialization, Inc.
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER
Payment Record ID 696048971
11/12/2019 Research In-kind items and services Drug $50.00 Details
Payment from Otsuka Pharmaceutical Development & Commercialization, Inc.
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER
Payment Record ID 696048969
11/12/2019 Research In-kind items and services Drug $50.00 Details
Payment from Otsuka Pharmaceutical Development & Commercialization, Inc.
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER
Payment Record ID 696048967
11/12/2019 Research In-kind items and services Drug $182.93 Details
Payment from Otsuka Pharmaceutical Development & Commercialization, Inc.
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER
Payment Record ID 696048965
11/12/2019 Research In-kind items and services Drug $247.47 Details
Payment from Otsuka Pharmaceutical Development & Commercialization, Inc.
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER
Payment Record ID 696048963
11/11/2019 Research Cash or cash equivalent Drug $18.01 Details
Payment from Otsuka Pharmaceutical Development & Commercialization, Inc.
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER
Payment Record ID 696048961
11/11/2019 Research In-kind items and services Drug $125.00 Details
Payment from Otsuka Pharmaceutical Development & Commercialization, Inc.
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER
Payment Record ID 696048959
11/11/2019 Research In-kind items and services Drug $182.93 Details
Payment from Otsuka Pharmaceutical Development & Commercialization, Inc.
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER
Payment Record ID 696048957
11/11/2019 Research In-kind items and services Drug $541.60 Details
Payment from Otsuka Pharmaceutical Development & Commercialization, Inc.
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER
Payment Record ID 696048955
09/26/2019 General (Non-Research) In-kind items and services Travel and Lodging $485.40 Details
Payment from Roche Products Limited
Payment Record ID 681067533
09/26/2019 General (Non-Research) In-kind items and services Food and Beverage $563.94 Details
Payment from Roche Products Limited
Payment Record ID 681067335
09/26/2019 General (Non-Research) In-kind items and services Travel and Lodging $561.18 Details
Payment from Roche Products Limited
Payment Record ID 681067331
08/02/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $4200.00 Details
Payment from Shire North American Group Inc
Payment Record ID 565820099
07/28/2018 General (Non-Research) In-kind items and services Travel and Lodging $25.00 Details
Payment from Shire North American Group Inc
Payment Record ID 565820094
07/28/2018 General (Non-Research) In-kind items and services Food and Beverage $5.00 Details
Payment from Shire North American Group Inc
Payment Record ID 565820091
07/28/2018 General (Non-Research) In-kind items and services Travel and Lodging $18.00 Details
Payment from Shire North American Group Inc
Payment Record ID 565820081
10/27/2016 General (Non-Research) Cash or cash equivalent Food and Beverage $34.74 Details
Payment from Supernus Pharmaceuticals, Inc.
Payment Record ID 401161202
;